An Observational Study of Induction Therapy With Fuzeon (Enfuvirtide) in Combination With Antiretroviral Drugs in Patients With HIV-1 Infection

A Study of Fuzeon (Enfuvirtide) With an Integrase Inhibitor Plus Optimized Background in Treatment-Experienced HIV-1 Infected Patients

NCT00488059 ·Status: TERMINATED ·Phase: PHASE4

ESP Study: A Study to Assess the Effect of Adding Fuzeon (Enfuvirtide) to an Antiretroviral Regimen in Fuzeon-Naive Patients With Sustained HIV Viral Suppression.

NCT00461266 ·Status: WITHDRAWN ·Phase: PHASE4

Fuzeon (Enfuvirtide) Early Access Program for Patients With HIV-1 Infection

NCT00050856 ·Status: COMPLETED ·Phase: PHASE3

Cohort Study for Patients Using Fuzeon (Enfuvirtide)

NCT00216359 ·Status: UNKNOWN

A Study of Enfuvirtide (Fuzeon) in Participants With Advanced Human Immunodeficiency Virus (HIV) Infection

NCT02582983 ·Status: COMPLETED ·Phase: PHASE4

Fuzeon Viral Decay Pilot Study

NCT00334022 ·Status: COMPLETED ·Phase: NA

BLQ Study: A Study of a Protease Inhibitor With Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With HIV-1.

NCT00326963 ·Status: COMPLETED ·Phase: PHASE4

A Study to Evaluate the Safety and Efficacy of Adding Enfuvirtide to Oral Highly Active Antiretroviral Therapy (HAART) in Human Immunodeficiency Virus (HIV) Patients With Prior Treatment Experience

NCT00487188 ·Status: COMPLETED ·Phase: PHASE4

Pilot Study Evaluating Interruption of Enfuvirtide (Fuzeon, T20) in Patients With Enfuvirtide Resistance

NCT00187551 ·Status: COMPLETED ·Phase: PHASE4

Prospective Evaluation Among Patients Infected by HIV 1 in Virological Failure Owing to Lack of Compliance, of the Benefit in Terms of Compliance of an Optimised Antiretroviral Treatment With Enfuvirtide (Fuzeon) Associated With Two Active Molecules

NCT00937729 ·Status: TERMINATED

Study to Evaluate Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) in Virologically-Suppressed HIV-1 Infected Adults Harboring the Archived Isolated NRTI Resistance Mutation M184V/M184I

NCT02616029 ·Status: COMPLETED ·Phase: PHASE3

Switch Study to Evaluate F/TAF in HIV-1 Positive Participants Who Are Virologically Suppressed on Regimens Containing FTC/TDF

NCT02121795 ·Status: COMPLETED ·Phase: PHASE3

QUALITE Study - A Study of Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With Human Immunodeficiency Virus-1 (HIV-1) Infection

NCT00232908 ·Status: COMPLETED ·Phase: PHASE4

Observational Study in Patients With HIV Infection Type 1 After Switching to a Viramune®-Containing Therapy Regimen

NCT02191332 ·Status: COMPLETED

Therapeutic Intensification Plus Immunomodulation in HIV-infected Patients

NCT01019551 ·Status: COMPLETED ·Phase: PHASE2

Observational Study Of A Protease Inhibitor (PI) Containing Regimen In Subjects With PI Mutations Selected During Prior Treatment With GW433908 (Fosamprenavir)

NCT00242840 ·Status: COMPLETED ·Phase: PHASE3

Observational Study With Antiretroviral Treated Patients Switching to Nevirapine Plus Two Nucleoside Reverse Transcriptase Inhibitor (NRTI) Regimens

NCT02191319 ·Status: COMPLETED

Early Fast-Track Versus Standard Care for Persons With HIV Initiating TLD

NCT04311944 ·Status: UNKNOWN ·Phase: NA

Impact of Extremely Early Antiretroviral Therapy to Reduce VIral REservoir and Induce Functional CURE of HIV-1 Infection

NCT02588820 ·Status: UNKNOWN ·Phase: PHASE3

Phase 3 Open-Label Study to Evaluate Switching From Optimized Stable Antiretroviral Regimens Containing Darunavir to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) Plus Darunavir (DRV) in Treatment Experienced HIV-1 Positive Adults

NCT01968551 ·Status: COMPLETED ·Phase: PHASE3

Administration of High Doses of Antiretroviral Drugs to Eliminate the Latent HIV-1 Reservoir

NCT06640192 ·Status: RECRUITING ·Phase: PHASE2

Pilot Study on Once Daily FTC, ddI, Efavirenz Combination in Antiretroviral Naive HIV Infected Adults

NCT00196599 ·Status: COMPLETED ·Phase: PHASE2

Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor (PI) and Two Nucleoside Reverse Transcriptase Inhibitors (NRTIs) to a Fixed-dose Tablet Containing Emtricitabine/Rilpivirine/Tenofovir DF

NCT01252940 ·Status: COMPLETED ·Phase: PHASE3

BOSS Study: A Study of Fuzeon Using the Needle-Free Biojector 2000 in Patients With HIV-1 Infection

NCT00337701 ·Status: COMPLETED ·Phase: PHASE4

Study to Evaluate Switching From an E/C/F/TAF Fixed-Dose Combination (FDC) Regimen or a TDF Containing Regimen to B/F/TAF FDC in Human Immunodeficiency Virus-1 (HIV-1) Infected Participants Aged ≥ 65 Years

NCT03405935 ·Status: COMPLETED ·Phase: PHASE3